Clinical Trial Update: Phase II Study Evaluating the Efficacy and Safety of KX-826 [Phase 2]

View source ↗

Summary

Phase II study evaluating the efficacy and safety of KX-826 in androgenetic alopecia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• KX-826

Snippet

Sponsor: Suzhou Kintor Pharmaceutical Inc, | Conditions: Androgenetic Alopecia (AGA) | Phase 2 | Status: COMPLETED